McDonald's China Faces Backlash for Food Hygiene Violations 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Electric air taxis are on the way – quiet eVTOLs may be flying passengers as early as 2025 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Green industry yes, conservation no: a budget for people, not for nature 
ALWAYTH x Adidas Samba: Revolutionizing Sneaker Culture with Fashion-Forward Collaboration 
Interest rates: the ugly dilemma facing Europe’s central banks – and why it’s a mistake to cut too soon 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
High interest rates aren’t going away anytime soon – a business economist explains why 
How supermarkets are changing their branding to make you think they’re cheaper 
Reducing energy demand and improving efficiency will help prevent the next gas crisis 
Latest inflation figures are good news 
Supporting ‘democracy’ is hard for many who feel government and the economy are failing them 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Samsung Biologics just opened the largest Contract Development and Manufacturing Organization (CDMO) plant in the world, and it is located in Incheon, South Korea. The biotech firm is now hoping that through its new pharmaceutical facility, it will be able to replicate the success of its chip manufacturing business.
Samsung Biologics inaugurated the plant on Tuesday, Oct. 11, and it was attended by the vice chairman of Samsung Electronics, Lee Jae Yong. The facility is now the biopharma firm’s fourth factory.
The company usually has an annual production capacity of 240,000 liters and this will now become 420,000 liters as the new plant starts its partial operation. The construction of the Songdo plant began in 2020, and it is expected to go into full operation next year.
As per Korea Joongang Daily, once it runs in full force, Samsung Biologics is expecting to further increase its production capacity up to 620,000 liters. The company said this amount is equivalent to almost 30% of the global contract manufacturing capacity for biopharma firms.
With this volume, Samsung Biologics defeated Switzerland’s Lonza Group AG and Germany's Boehringer Ingelheim pharmaceutical and biotech companies.
In any case, Samsung invested KRW2 trillion or about $1.4 billion for the construction of its new Songdo plant, and in the future, the company may spend a total of KRW7 trillion on building its fifth, sixth, seventh, and eighth plants in the same region but on another site. Samsung Biologics is expanding its facilities to accommodate more orders from its major global clients, such as Pfizer, GlaxoSmithKline, Moderna, Eli Lilly, and AstraZeneca.
Meanwhile, the Samsung chief met with the senior executives of Samsung Biologics and Samsung Bioepis after the inauguration ceremony for the Songdo factory. They talked about mid and long-term strategies to improve competitiveness as CDMO and a biosimilar manufacturer.
The Korea Times reported that at the meeting, Lee Jae Yong vowed to put in a new investment of KRW7.5 trillion or $5.2 billion to widen the gap from its rivals in the bio business and move ahead to become the leader in the industry. He said that Samsung will release the fund for its biotech unit by 2032.
